BofA lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $9 from $10 and keeps a Buy rating on the shares. While stating that “there wasn’t much new from Werewolf’s 1Q print,” the firm still sees reasons to be encouraged about the second half outlook, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics Receives Nasdaq Deficiency Notice
- Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
- Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
- Werewolf Therapeutics Reports Q1 2025 Financial Results
- Werewolf Therapeutics files $150M mixed securities shelf